Stephen M. Stahl – författare

For decades, psychiatry has focused on initiating treatment-which medication to prescribe, in what dose, and for how long. But what happens when treatment needs to stop? How a medication is stopped is just as important as how it is started, and abrupt discontinuation can lead to unnecessary suffering, relapse, and often preventable withdrawal symptoms. Based on the principles of the bestselling Stahl's Prescriber's Guide, this essential resource provides user-friendly guidance on deprescribing or switching psychotropic medications safely and effectively. 64 medications are presented in a consistent format to facilitate rapid access to deprescribing information. Divided into color coded sections, the book allows the reader to identify key details about when and why to deprescribe, the risks and mechanisms of withdrawal, tapering protocols, cross-titration strategies, and how to distinguish withdrawal symptoms from relapse. Evidence-based recommendations and expert clinical insights make this a must-have manual for all psychiatric prescribers.

With the range of psychotropic drugs expanding and the usages of existing medications diversifying, we are pleased to present the Eighth Edition of the world's best-selling formulary in psychopharmacology. The new edition features seven brand new compounds as well as information about several newly approved formulations of existing drugs. Many important new indications are covered for existing drugs, as are updates to the profiles of the entire content and collection, including new injectable and transdermal formulations, as well as updated warnings and indications. The icons and Pearls have been refreshed throughout, and with the book's its easy-to-use, full-colour template-driven navigation system, Prescriber's Guide combines evidence-based data with clinically informed advice to support everyone who is prescribing in the field of mental health.

The new edition of 'Stahl's Illustrated Pharmacological Treatments for Psychosis' (previously entitled 'Stahl's Illustrated Antipsychotics') provides the essential practical support required by anyone treating people with psychosis in the field of mental health. Incorporating information on the newest indications, formulations, recommendations, and safety data, all presented in a clear concise manner alongside informative and easy-to-understand illustrations. 'Stahl's Illustrated Pharmacological Treatments for Psychosis 3e' is a concise guide, with all concepts illustrated by full-color figures and tables, that will be familiar to readers of 'Stahl's Essential Psychopharmacology' and the 'Prescriber's Guide'. The visual learner will find that this book makes psychopharmacological concepts easier to master, and the non-visual learner will enjoy this book's short explanations of complex psychopharmacological concepts. Each chapter builds upon previous ones, synthesizing information about basic biology, diagnostics, treatment plans, complications, and comorbidities. This book is the essential guide for mental health providers caring for psychiatric patients.

Drs. Stephen M. Stahl and Bret A. Moore have created an instant classic in Anxiety Disorders: A Guide for Integrating Psychopharmacology and Psychotherapy. Anxiety Disorders is a comprehensive reference for the psychiatry and psychology student, intern, or resident, early career psychiatrist or psychologist, and the busy clinician. It distills the most important information regarding combined treatments for anxiety and presents the material in an easily accessible, understandable, and readable format. Each chapter addresses a specific type of disorder: PTSD, panic, generalized anxiety, obsessive-compulsive and other disorders, and is authored by prominent clinicians with years of experience in providing integrated, individualized treatments. With its thorough exploration of psychopharmacological treatments, psychosocial treatments, and, crucially, the integration of the two, Anxiety Disorders is a text no 21st-century clinician or student can afford to be without.

Drs. Stephen M. Stahl and Bret A. Moore have created an instant classic in Anxiety Disorders: A Guide for Integrating Psychopharmacology and Psychotherapy. Anxiety Disorders is a comprehensive reference for the psychiatry and psychology student, intern, or resident, early career psychiatrist or psychologist, and the busy clinician. It distills the most important information regarding combined treatments for anxiety and presents the material in an easily accessible, understandable, and readable format. Each chapter addresses a specific type of disorder: PTSD, panic, generalized anxiety, obsessive-compulsive and other disorders, and is authored by prominent clinicians with years of experience in providing integrated, individualized treatments. With its thorough exploration of psychopharmacological treatments, psychosocial treatments, and, crucially, the integration of the two, Anxiety Disorders is a text no 21st-century clinician or student can afford to be without.

Integrating Psychotherapy and Psychopharmacology: A Handbook for Clinicians is a practical guide for the growing number of mental-health practitioners searching for information on treatments that combine psychopharmacology, psychotherapy, and psychosocial rehabilitation. Research shows that combined approaches are among the most effective ways to treat an increasing number of psychiatric disorders. However, though these combined treatments are becoming the everyday practice of psychiatrists, psychologists, and other mental-health professionals, identifying the right treatment plan can be notoriously difficult, and clinicians are often left scrambling to answer questions about how to design and customize their treatment strategies. In Integrating Psychotherapy and Psychopharmacology, readers will find these questions fully addressed and the answers explained, and they’ll come away from the book with a toolbox full of strategies for helping their patients improve symptoms, achieve remission, and stay well using a combination of drug and psychological treatments.

Integrating Psychotherapy and Psychopharmacology: A Handbook for Clinicians is a practical guide for the growing number of mental-health practitioners searching for information on treatments that combine psychopharmacology, psychotherapy, and psychosocial rehabilitation. Research shows that combined approaches are among the most effective ways to treat an increasing number of psychiatric disorders. However, though these combined treatments are becoming the everyday practice of psychiatrists, psychologists, and other mental-health professionals, identifying the right treatment plan can be notoriously difficult, and clinicians are often left scrambling to answer questions about how to design and customize their treatment strategies. In Integrating Psychotherapy and Psychopharmacology, readers will find these questions fully addressed and the answers explained, and they’ll come away from the book with a toolbox full of strategies for helping their patients improve symptoms, achieve remission, and stay well using a combination of drug and psychological treatments.

As with Stahl's Essential Psychopharmacology, 3rd edition and The Prescriber's Guide, Attention Deficit Hyperactivity Disorder is a heavily illustrated title with a fun approach to theories. Stahl has been at the heart of significant advances in the treatment of ADHD in the past ten years, as new psychopharmacologic medications and cognitive and behavioral therapy techniques have been introduced into practice. The visual learner will find that these books make psychopharmacology concepts easy to master, while the non-visual learner will enjoy a shortened text version of complex psychopharmacology concepts. Novices to the series will find that the well-structured graphics and visual vocabulary can help build a vivid conception of complex pharmacologies. The complementary tables and algorithms provide clinical strategies and tips for drug dosaging, and the Suggested Reading section at the end of each book is an invaluable tool to guide the reader to more in-depth learning on particular concepts.

As with Stahl's Essential Psychopharmacology and The Prescriber's Guide, Chronic Pain and Fibromyalgia is a full-colour title with a fun approach to theories. Stahl has been at the heart of many recent advances in the understanding of pain psychology, which has been reflected in the development of a new and wide variety of psychopharmologic and non-psychopharmologic pain medications. The visual learner will find that these books make psychopharmacology concepts easy to master, while the non-visual learner will enjoy a shortened text version of complex psychopharmacology concepts. Readers will find that the well-structured vocabulary combines with tables and algorithms to help build a vivid conception of current clinical strategies. The title is essential reading for pharmaceutical and mental health professionals, neurologists and pain management specialists. The Suggested Reading section at the end of the book is an invaluable tool for more in-depth learning on particular concepts.

In medical education a lot of attention is given to what is said, but less consideration is given to how it is said. There is sometimes a misplaced focus on the content at the expense of the experience for the learner. Best Practices in Medical Teaching illustrates the general principles of effective medical presentation. Stahl and Davis are leading experts in medical communication and they effectively explain the practice and methods behind their success. Applying the principles of adult learning, they provide examples of how to design a successful lecture and teach the reader how to influence the behaviors of their audience. Each chapter ends with a chapter summary, progress check, and a performance self-assessment test to ensure that the concepts are understood. This book is an essential guide for all those involved in the process of educating the next generation of doctors and supporting them through their training.

The Stahl's Illustrated books are a series of pocket-sized, mid-priced, themed volumes. They distil theoretical information from the Stahl's Essential Psychopharmacology volume and combine this with practical data from The Prescriber's Guide. They are illustration heavy and designed to encourage speedy learning of both concepts and applications. The visual learner will find that these books make the concepts easier to master, and the non-visual learner will appreciate the clear, shortened text on complex psychopharmacological concepts. This volume covers the latest developments in our understanding of post-traumatic stress disorder and anxiety. As well as covering the full range of management options, there is a specific focus on the implications for military populations. The Stahl's Illustrated series appeals to the widest possible audience of mental health professionals, and not just those with expertise in psychopharmacology.

Designed with the distinctive, user-friendly presentation Dr Stahl's audience know and love, this new stream of Stahl books capitalize on Dr Stahl's greatest strength - the ability to address complex issues in an understandable way and with direct relevance to the everyday experience of clinicians. The book describes a wide-ranging and representative selection of clinical scenarios, making use of icons, questions/answers and tips. It follows these cases through the complete clinical encounter, from start to resolution, acknowledging all the complications, issues, decisions, twists and turns along the way. The book is about living through the treatments that work, the treatments that fail, and the mistakes made along the journey. This is psychiatry in real life - these are the patients from your waiting room - this book will reassure, inform and guide better clinical decision making.

Relying upon the best-selling third edition of Stahl's Essential Psychopharmacology, Dr Stephen M. Stahl has revised chapters covering depression and bipolar disorder for this edition. Significantly revised and expanded it is essential for professionals treating depression and students needing a straight forward illustrated guide to drug mechanism and current research. It includes advances in neurobiology and recent clinical developments to explain with renewed clarity clinical advances in antidepressant therapy and includes new coverage of sleep disorders and disorders of impulse control. The fully revised text is complemented by many new illustrations and enhanced to reflect new knowledge and topics not covered in the previous edition. More than one-third longer than the previous edition, it is essential reading for professionals treating psychosis and students learning the mechanisms of drug reactions. Intended as a primer text covering all aspects of treatment for psychosis and related conditions, this concise volume can nevertheless be read cover to cover by experts and novices alike. Accreditation and Credit Designation Statements The Neuroscience Education Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Neuroscience Education Institute designates this educational activity for a maximum of 90.0 AMA PRA Category 1 Credits(tm). Physicians should only claim credit commensurate with the extent of their participation in the activity. Sponsorship Information Sponsored by Neuroscience Education Institute Support This activity is supported solely by the sponsor. Neither the Neuroscience Education Institute nor Stephen M. Stahl, MD, PhD has received any funds or grants in support of this educational activity.

All of the titles in the Stahl's Illustrated series are designed to be fun. Concepts are illustrated by full-color images that will be familiar to all readers of Stahl's Essential Psychopharmacology, 3rd Edition and The Prescriber's Guide. The visual learner will find that these books make psychopharmacology concepts easy to master, while the non-visual learner will enjoy a shortened text version of complex psychopharmacology concepts. Within each book, each chapter builds on previous chapters, synthesizing information from basic biology and diagnostics to building treatment plans and dealing with complications and comorbidities. Novices may want to approach Stahl's Illustrated series by first looking through all the graphics and gaining a feel for the visual vocabulary. Readers more familiar with these topics should find that going back and forth between images and text provides an interaction with which to vividly conceptualize complex pharmacologies. And, to help guide the reader toward more in-depth learning about particular concepts, each book ends with a Suggested Reading section.

In response to rapid developments in psychopharmacology, this is a spin-off from Stephen M. Stahl's new, completely revised and updated third edition of his much-acclaimed Prescriber's Guide. It covers the most important drugs in use today for psychosis and mood stabilization. In full color throughout, and with four or more pages for each of the antipsychotic drugs, Stephen M. Stahl distills his great expertise into a pragmatic formulary that gives all the information a prescriber needs to treat patients effectively. Each drug is covered in five categories: general therapeutics, dosing and use, side effects, special populations, and pearls. Target icons appear next to key categories for each drug so that the prescriber can go easily and instantly to the information needed. Several indices are included, listing drugs by name (generic and international) and use. In addition, Dr Stahl indicates which drugs have FDA approval and also gives the FDA Use-in-Pregnancy ratings.

The World Health Organization defines depression as a primary contributor to the global burden of disease and predicts it will become the second leading cause of death by 2020. The need to develop effective therapies has never been so pressing. Current antidepressant drugs have several limitations. This 2010 book looks at the future of mood-disorder research, covering the identification of new therapeutic targets, establishing new preclinical models, new medicinal chemistry opportunities, and fostering greater understanding of genetic influences. These strategies are likely to help build a better picture of the disease process, and lead to new opportunities for patient stratification and treatment. The ultimate goal for this strand of research is to develop more personalized and effective treatments for this chronic and debilitating condition. This is essential reading for all those involved in psychopharmacologic drug development, and mental health clinicians seeking a preview of discoveries soon to influence their practice.

Central Nervous System disorders have an enormous impact on individuals and on society as a whole. The development of better treatments is crucial and is a major focus of pharmaceutical and biotechnology companies. This book explains the complicated process of CNS drug development in a way that is engaging for any interested professional or student. Chapters cover each stage of drug development, from pre-clinical research through all phases of clinical trials, to reporting to the regulatory authorities. Other key issues covered include strategic considerations, regulatory constraints, dissemination of results and ethical considerations. The user-friendly format and style enable readers to find important information quickly and easily. Written and edited by experts from different sectors actively engaged in CNS drug development, this is a unique resource for drug developers, investigators, academics and clinicians.

Fully updated, this new edition continues to present information in a clear, illustrative, and concise manner. Replacing both Stahl's Illustrated Antidepressants and Stahl's Illustrated Mood Stabilizers, this concise and illustrated guide examines the full spectrum of symptoms included in mood disorders from mania to depression to mixed states in between, the neurocircuitry underlying these symptoms, and the evidence-based therapeutic targets for treatment. Concepts are illustrated by full-color figures, images, and tables making psychopharmacology concepts within this book easy to master for the visual learner. Non-visual learners can enjoy a shortened text version of complex psychopharmacology concepts. Each chapter builds on previous chapters, synthesizing information from basic biology and diagnostics to building treatment plans and dealing with complications and comorbidities. The interaction between the images and text allows the reader to vividly conceptualize complex pharmacologies and a Suggested Reading section guides readers toward more in-depth learning about particular concepts.

Clinicians recognize that monitoring psychotropic levels provides invaluable information to optimize therapy and track treatment adherence, but they lack formal training specifically focused on the use of plasma antipsychotic levels for these purposes. As new technologies emerge to rapidly provide these results, the opportunity to integrate this information into clinical care will grow. This practical handbook clarifies confusing concepts in the literature on use of antipsychotic levels, providing clear explanations for the logic underlying clinically relevant concepts such as the therapeutic threshold and the point of futility, and how these apply to individual antipsychotics. It offers accessible information on the expected correlation between dosages and trough levels, and also provides a clear explanation of how to use antipsychotic levels for monitoring oral antipsychotic adherence, and methods to help clinicians differentiate between poor adherence and variations in drug metabolism. An essential resource for psychiatrists, psychiatric nurse practitioners, and mental health professionals worldwide.

This brand-new fourth volume in Stahl's Case Studies series presents a selection of clinical case studies in child and adolescent psychopharmacology, taken from Dr. Strawn's clinics and consultations. These cases illustrate common questions that are routinely asked by Dr. Strawn's peers in consultations and which represent dilemmas in the day-to-day practice of pediatric psychopharmacology. Followings a consistent, user-friendly layout, each case features icons, tips and questions about diagnosis and management as it progresses over time, a pre-case self-assessment question, followed by the correct answers at the end of the case. Formatted in alignment with the American Board of Psychiatry and Neurology's maintenance of psychiatry speciality certification, cases address multifaceted issues in a relevant and understandable way. Covering a wide-ranging and representative selection of clinical scenarios, each case is followed through the complete clinical encounter, from start to resolution, acknowledging all the complications, issues, decisions, twists and turns along the way.

Mental health professionals routinely make treatment decisions without necessarily having an overarching perspective about optimal next steps. This important new book provides them with reader-friendly, pragmatic strategies to approach clinical problems as testable hypotheses. It discusses how to apply concepts based on decision analytic theory using risk-benefit analyses, contingency planning, measurement-based care, shared decision making, pharmacogenetics, disease staging, and machine learning. Readers will learn how these tools can help them craft optimal pharmacological and psychosocial interventions tailored to the needs of an individual patient. The book covers topics such as diagnostic ambiguity, interview technique, applying statistical concepts to individual patients, artificial intelligence, and managing high-risk, treatment-resistant, or demanding and difficult patients. Valuable clinical vignettes are featured throughout the book to illustrate common dilemmas and scenarios where the relative merits of competing treatment options invite a more iterative than definitive approach. For all healthcare professionals who prescribe psychotropic medications.

Worldwide efforts to promote greater lithium use for mood disorders have increased the need for evidence-based guidance addressing key questions related to initiation, monitoring and adverse effect management. This practical handbook provides clinicians with a detailed explanation of lithium's renal journey, how this informs our understanding of polyuria pathogenesis and how medications or hyponatremia can alter lithium clearance. Covering efficacy, pharmacokinetics, toxicity, discontinuation, and use in special patient groups including pregnant and breastfeeding women, older or younger patients, each section also provides a detailed background for its suggested logical approach to managing lithium's renal and other adverse effects. Using the latest data, the book outlines rationales for specific management decisions, and prioritizes options to provide clinical guidance on the best course of action. Colour-coded lists and tables, bulleted text, and diagrams illustrate important points throughout, helping to make information accessible and easy-to-digest. An essential resource for mental health professionals worldwide.

This extensively revised second edition provides a user-friendly step-by-step manual on the range of psychotropic medications prescribed for children and adolescents by clinicians and nurse practitioners. Boasting nearly double the medications of the first edition, it features new sections related to pharmacokinetics and pharmacogenetics in children and adolescents alongside algorithms for addressing frequently encountered disorders such as anxiety, depression, bipolar disorder, ADHD, and OCD. Based on the best-seller, Stahl's Prescriber's Guide, and using a full-color template-driven navigation system, it combines evidence-based data with clinically informed guidance to support prescribers in the field. Each drug is presented in the same classic design format with illustrated guidance on dosing, titration, and pharmacogenetics/metabolism. Color-coded sections distinguish clearly the information presented on therapeutics, safety and tolerability, dosing and use, what to expect, and the art of psychopharmacology, and are followed by updated and new key references. A must-have guide for all mental health professionals.

This sixth volume in Stahl's Case Studies series presents a selection of clinical case studies in forensic psychopharmacology. Focusing on severe syndromes and clinical presentations found in the severely mentally ill who have become justice involved and/or required care in a state or forensic hospital facility, these cases illustrate questions that are routinely asked in psychiatric consultations. Following a consistent, user-friendly layout, each case features icons, tips and questions about diagnosis and management as it progresses over time, a pre-case self-assessment question, followed by the correct answers at the end of the case. Formatted in alignment with the American Board of Psychiatry and Neurology's maintenance of psychiatry specialty certification, cases address multifaceted issues in an understandable way. Covering a wide-ranging and representative selection of clinical scenarios, each case is followed through the complete clinical encounter, from start to resolution, acknowledging the complications, issues, decisions, twists and turns along the way.

With the range of psychotropic drugs expanding and the usages of existing medications diversifying, we are pleased to present the Eighth Edition of the world's best-selling formulary in psychopharmacology. The new edition features seven brand new compounds as well as information about several newly approved formulations of existing drugs. Many important new indications are covered for existing drugs, as are updates to the profiles of the entire content and collection, including new injectable and transdermal formulations, as well as updated warnings and indications. The icons and Pearls have been refreshed throughout, and with the book's its easy-to-use, full-colour template-driven navigation system, Prescriber's Guide combines evidence-based data with clinically informed advice to support everyone who is prescribing in the field of mental health.

Recreational drugs that were once proscribed are now being explored as new pharmacotherapies. This topical book provides a balanced guide to new and far-reaching changes in our health system and our drug laws. Written by leading scientists, practitioners and researchers, it examines the evidence, discusses the history and context, and describes the pharmacology of recreational drugs that are being repurposed as medical treatments as well as recreational drugs that are currently being investigated. Amongst the drugs covered are psilocybin, cannabis, ketamine, MDMA, amphetamine and methylphenidate. Where known, the mechanisms of action, pharmacokinetics, putative indications, and safety and tolerability are described for each agent. Drugs used by indigenous communities for ritual purposes, currently being considered for treatment by the mainstream medical establishment, are also investigated. This is an up-to-date evidence-based resource for all people interested in the medical use of recreational drugs.

This unique book offers a methodical exploration of biological, social, and ethical topics on the treatment (or lack thereof) of psychotic brain disease. Part I provides an empirical engagement with neuroscience and covers the neurobiology and pharmacology of schizophrenia, providing the reader with a current understanding of the disease. Topic areas include anosognosia, community treatments, and early intervention. Part II looks at international policy approaches to schizophrenia featuring topics such as the policy, funding, and historical elements contributing to frequently misguided approaches to severe brain disease, and it explains why some societies won't/can't support human beings with psychotic disease. Part III focuses on neuroethics and asks: 'What is right?' through chapters discussing the concepts of consciousness and free will, as well as the principles of nonmaleficence, beneficence, autonomy, and justice. Collectively the comprehensive approach of this book allows the reader to gain a full understanding of the ethical and clinical complexities in treating schizophrenia.